Gürel İlaç and Ribogen İlaç Join Forces: Strategic Agreement on Two Products

Gürel İlaç and Ribogen İlaç sign strategic partnership in Turkey's pharmaceutical market. Under the agreement, sales, marketing and distribution rights for two licensed products of Gürel İlaç in Turkey were transferred to Ribogen İlaç.

Gürel İlaç, operating in Turkey's pharmaceutical sector, and Ribogen İlaç, which develops innovative and patient-focused healthcare solutions, have established a new strategic partnership aimed at strengthening growth and product access.

Under the agreement signed on 3 July 2026, the sales, marketing and distribution rights in Turkey for two products licensed to Gürel İlaç and containing the active substances Asemetacin and Vitamin B1 + Vitamin B6 + Vitamin B12 + Thioctic acid were transferred to Ribogen İlaç.

Combining the expertise of two companies
The partnership aims to bring together Gürel İlaç's product portfolio and pharmaceutical sector experience with Ribogen İlaç's capabilities in promotion, marketing and field organization.

The parties aim to make the products available to a wider patient population and establish a stronger market presence in the relevant therapeutic areas.

The strategic agreement is expected to contribute to more effective service provision to healthcare professionals by complementarily utilizing the expertise of both companies, and to strengthen patient access to treatment options.

Gürel İlaç continues to strengthen its portfolio
Gürel İlaç, a domestic pharmaceutical company focused on human health, continues its activities in the healthcare sector through its work in licensing, business development, marketing and product management.

The company, building a product portfolio across different therapeutic areas, aims to develop its portfolio through national and international partnerships. Following scientific developments, Gürel İlaç positions quality, reliability and long-term business partnerships as fundamental elements of its operations.

Ribogen İlaç expands its field force
Istanbul-based Ribogen İlaç focuses on developing innovative solutions in the healthcare sector in line with its science and patient-focused approach.

Aiming to be a reliable business partner for physicians, pharmacists and patients, the company continues to develop solutions to changing healthcare needs by following scientific developments with its expert team.

Through strategic partnerships it has established, Ribogen İlaç aims to reach its products and services to wider audiences and create sustainable value in the healthcare ecosystem.

Strategic partnership to support growth targets
The agreement between Gürel İlaç and Ribogen İlaç is intended to be one of the important steps in both companies' long-term growth strategies.

With sales, marketing and distribution processes supported by Ribogen İlaç's field organization and commercial capabilities, the aim is to strengthen access of the products under the agreement in Turkey's pharmaceutical market.